{"id":"modified-bismuth-containing-eradication-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Darkening of stool"},{"rate":null,"effect":"Metallic taste"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bismuth salts accumulate in H. pylori cells and damage the bacterial cell wall and membrane, while also inhibiting the urease enzyme that the bacterium uses to survive in acidic gastric environments. This combination of direct bactericidal activity and enzyme inhibition makes bismuth an effective component of multi-drug eradication regimens for H. pylori infection.","oneSentence":"Bismuth-containing compounds eradicate Helicobacter pylori by disrupting bacterial cell wall integrity and inhibiting urease enzyme activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:31.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication as part of combination therapy"}]},"trialDetails":[{"nctId":"NCT07146594","phase":"PHASE4","title":"Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Athens Medical Center","startDate":"2025-08-20","conditions":"Helicobacter Pylori Gastritis, Helicobacter Eradication","enrollment":150},{"nctId":"NCT03665428","phase":"PHASE4","title":"Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2018-07-16","conditions":"Helicobacter Pylori Infection","enrollment":233},{"nctId":"NCT03616405","phase":"PHASE4","title":"Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-04-01","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT03658733","phase":"PHASE4","title":"A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-12-15","conditions":"Helicobacter Pylori Infection","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Modified bismuth-containing eradication treatment","genericName":"Modified bismuth-containing eradication treatment","companyName":"Athens Medical Center","companyId":"athens-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A bismuth-based combination therapy that eradicates Helicobacter pylori infection through multiple antimicrobial mechanisms. Used for Helicobacter pylori infection eradication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}